[webinar] Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program
Watch this webinar to learn about how the DRIVE-MRT solution enables the rationalization, design and optimization of targeted and effective radiopharmaceuticals against specific cancers, with a demonstration of preclinical proof of acceptable safety margins and a clinical support plan.
Speakers :
Dr Meddy El Alaoui, CSO, Covalab
Dr Frederic Boschetti, CEO, CheMatech
Dr Cyril Berthet, Head of Pharmaco-imaging and Molecular Radiotherapy Department, Oncodesign
Dr Andreas Kluge, General Manager, ABX-CRO
Abstract :
Preclinical and clinical evaluation of radiopharmaceuticals can be sometimes seen as straightforward compared to non-radioactive molecules as the injected doses are often below toxic doses. However, the development of theranostics requires highly specific expertise and strong collaboration between preclinical and clinical development. Therefore, the discovery and development process requires multiple and highly specialized skills, the combination of which are often nonexistent in a single structure, even more so in the specialized field of radiopharmaceuticals.
The DRIVE-Molecular RadioTherapy (MRT) offer is based on the complementary knowledge and know-how of each partner (Covalab, CheMatech, ABX-CRO and Oncodesign) representing an experienced and innovative network in nuclear medicine. Thus, the four companies have built a joint value proposition in which the generation of radiolabeled biological vectors, chelator production, design of the bioconjugated lead, preclinical proof of concept and the design of the regulatory and clinical package are managed effectively and efficiently under one roof.
More info: https://www.oncodesign.com/services/d...